Status:

UNKNOWN

Pro-vascular Regenerative Cell Exhaustion in Women With Polycystic Ovarian Syndrome

Lead Sponsor:

Canadian Medical and Surgical Knowledge Translation Research Group

Conditions:

Polycystic Ovary Syndrome

Eligibility:

FEMALE

30+ years

Brief Summary

PCOS-RCE is an observational, cross-sectional, two-arm study that is aimed at determining if an established diagnosis of polycystic ovarian syndrome (PCOS) influences the number of blood vessel-formin...

Detailed Description

Individuals with polycystic ovarian syndrome (PCOS) have been reported to be at higher risk of cardiovascular disease when compared to those without PCOS. While differential environmental exposures an...

Eligibility Criteria

Inclusion

  • Capable and willing to provide informed consent
  • Females aged 30 and above
  • Must meet criteria for one of the following two groups:
  • Documented diagnosis of PCOS OR
  • Normal and regular menstrual cycles with no known diagnosis of PCOS

Exclusion

  • Menopause, as defined by 12 months of amenorrhea
  • Known causes of irregular menstrual bleeding caused by conditions other than PCOS
  • Known secondary causes of ovulatory dysfunction and/or hyperandrogenism
  • Current pregnancy, active lactation, or less than 6 months postpartum
  • Ongoing treatment with ovulation-inducing medication
  • History of hysterectomy and/or bilateral oophorectomy
  • Severe congestive heart failure (as defined by New York Heart Association - class IV)
  • Any life-threatening disease expected to result in death within the next 2 years
  • Any malignancy not considered cured. A subject is considered cured if there has been no evidence of cancer recurrence for the 5 years prior to screening.
  • Known severe liver disease
  • Known acquired immunodeficiency syndrome such as HIV
  • Current treatment with systemic or oral corticosteroid therapy or other immunosuppressive agents
  • Known autoimmune disorder (exception: type 1 diabetes)
  • Active infectious disease requiring antibiotic or anti-viral agents

Key Trial Info

Start Date :

June 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

April 1 2023

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT05410834

Start Date

June 1 2022

End Date

April 1 2023

Last Update

June 8 2022

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Centrum Services Newmarket

Newmarket, Ontario, Canada, L3Y 2N1

2

Diagnostic Assessment Centre

Scarborough Village, Ontario, Canada, M1S 4N6

3

Langstaff Medical Centre

Woodbridge, Ontario, Canada, L4L 1A6